Abstract
The Global Alliance for TB Drug Development and Tibotec have joined forces to develop a potential first-in-class drug for both drug-susceptible and drug-resistant tuberculosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Webb, S. Public–private partnership tackles TB challenges in parallel. Nat Rev Drug Discov 8, 599–600 (2009). https://doi.org/10.1038/nrd2955
Issue Date:
DOI: https://doi.org/10.1038/nrd2955
This article is cited by
-
Antibiotics in the clinical pipeline in 2013
The Journal of Antibiotics (2013)
-
Antibiotics in the clinical pipeline in 2011
The Journal of Antibiotics (2011)